Expanding Horizons in the Therapeutic Landscape for Relapsed Ovarian Cancer

Expanding Horizons in the Therapeutic Landscape for Relapsed Ovarian Cancer

Meeting Overview

We are pleased to invite you to join us on 28 September 2012 for Expanding Horizons in the Therapeutic Landscape for Relapsed Ovarian Cancer, an ESMO Vienna 2012 Industry Satellite Symposium to be held on 28 September 2012 in Vienna, Austria.

Agenda

12.30		Welcome and introduction Ignace Vergote, MD, PhD
12.35		Clinical opinion poll
12.40		The pathogenesis of relapsed ovarian cancer: Defining new targets Robert Coleman, MD
13.00		Clinical opinion poll
13.05		Platinum-sensitive, relapsed ovarian cancer: A look to the future Nicoletta Colombo, MD
13.25		Clinical opinion poll
13.30		How can we improve treatment of platinum-resistant/refractory disease? Thomas Herzog, MD
13.45		Ask the experts All Faculty
13.55		Closing comments Ignace Vergote, MD, PhD

Faculty

• Chair

  • Ignace Vergote, MD, PhD
    University Hospital Gasthuisberg
    Leuven, European Union
• 
  

• Faculty

  • Robert Coleman, MD
    University of Texas
    M. D. Anderson Cancer Center
    Houston, Texas, United States
  • Nicoletta Colombo, MD
    University of Milan-Bicocca
    Milan, Italy
  • Thomas Herzog, MD
    Columbia University Medical Center
    New York, New York, United States

Target Audience

This educational activity is specifically designed for medical oncologists, surgical oncologists, gynecologic oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with ovarian cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

• Describe the rationale and mechanisms of action for novel therapies in patients with relapsed ovarian cancer as it relates to disease pathogenesis
• Examine current and emerging treatment options for patients with platinum-sensitive ovarian cancer, including integration of novel targeted agents
• Discuss optimal treatment approaches for patients with platinum-resistant/refractory ovarian cancer based on patient and disease characteristics
• Evaluate strategies for improving the overall treatment of patients with relapsed ovarian cancer, including treatment individualization, biomarker use, and multidisciplinary management

Disclosures

Disclosure of Conflicts of Interest

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure of Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Register Now